Evaluation of serum-biomarkers as a surrogate marker for florid MS lesions (contrast enhancement) in patients with multiple sclerosis.

• Conditions: G35; Multiple sclerosis

• Registration Number: DRKS00016029
• Lead Sponsor: Klinikum der Johann Wolfgang Goethe-Universität Zentrum der Neurologie und Neurochirurgie

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2019-01-25
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 102

Inclusion Criteria

Planned implementation of a contrast enhanced cerebral or spinal MRI in patients with multiple sclerosis (including clinically isolated syndrome and radiologically isolated syndrome)

Exclusion Criteria

Age of patient < 18 years, other current present neurological diseases such as stroke, dementia, M. Parkinson or similar.

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The diagnostic accuracy of the S100B biomarker-test, determined through an ROC-analysis (area under the curve (AUC), sensitivity, specificity, positive and negative predictive value), which means the respective serum concentration, which separates patients with contrast enhancing lesions and without. The Parameter is measured in a time span of 5 days before or after the MRI.

Secondary Outcome Measures

Name	Time	Method
Secondary criteria are further biomarkers (GFAP, MMP-9, Endothelin) in a time span of 5 days before or after the MRI.